One such clinical trial (ICORG10–05/NCT01485926) was a phase II neoadjuvant study assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in early stage HER2+ breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.